We are live on ! Find out more
RHJA

Rice Hall James & Associates Portfolio holdings

AUM $2.05B
1-Year Est. Return 43.16%
This Fund
S&P 500
This Quarter Est. Return
+7.57%
1 Year Est. Return
+43.16%
3 Year Est. Return
+139.79%
5 Year Est. Return
+169.96%
10 Year Est. Return
+906.29%
AUM
$1.74B
AUM Growth
+$18.9M
Cap. Flow
-$61.5M
Cap. Flow %
-3.53%
Top 10 Hldgs %
23.9%
Holding
276
New
11
Increased
44
Reduced
193
Closed
16

Top Buys

Rank Stock Value
1
OABI icon
OmniAb
OABI
+$13M
2
DOCS icon
Doximity
DOCS
+$10.2M
3
LOB icon
Live Oak Bancshares
LOB
+$7.32M
4
RXO icon
RXO
RXO
+$7.31M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$6.78M

Top Sells

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$24.3M
2
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$12.4M
3
LGND icon
Ligand Pharmaceuticals
LGND
+$12.3M
4
XPO icon
XPO
XPO
+$7.84M
5
RXT icon
Rackspace Technology
RXT
+$5.42M

Sector Composition

Rank Sector Weight
1 Technology 27.01%
2 Healthcare 26.13%
3 Industrials 15.45%
4 Consumer Discretionary 11.41%
5 Communication Services 6.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXEL icon
226
Exelixis
EXEL
$13.1B
$1.22M 0.07%
75,813
-6,178
-8% -$101K
PUBM icon
227
PubMatic
PUBM
$809M
$1.11M 0.06%
86,500
-27,795
-24% -$436K
PGNY icon
228
Progyny
PGNY
$2.18B
$1.09M 0.06%
+35,119
New +$1.27M
MP icon
229
MP Materials
MP
$9.73B
$1.04M 0.06%
42,714
-3,231
-7% -$97.9K
COLM icon
230
Columbia Sportswear
COLM
$2.92B
$1M 0.06%
11,462
-244
-2% -$19.6K
TDY icon
231
Teledyne Technologies
TDY
$32B
$943K 0.05%
2,358
-81
-3% -$31.5K
BRK.B icon
232
Berkshire Hathaway Class B
BRK.B
$1.14T
$913K 0.05%
2,955
-1,229
-29% -$365K
SMID icon
233
Smith-Midland
SMID
$146M
$864K 0.05%
42,170
+1,573
+4% +$34.4K
RCM
234
DELISTED
R1 RCM Inc. Common Stock
RCM
$850K 0.05%
77,647
-91,208
-54% -$1.16M
TTD icon
235
Trade Desk
TTD
$6.29B
$810K 0.05%
18,069
+29
+0.2% +$1.47K
ABBV icon
236
AbbVie
ABBV
$438B
$805K 0.05%
4,981
-1,550
-24% -$238K
LLY icon
237
Eli Lilly
LLY
$1.1T
$783K 0.04%
2,140
– –
VVX icon
238
V2X
VVX
$2.6B
$745K 0.04%
+18,041
New +$715K
DENN
239
DELISTED
Denny's
DENN
$698K 0.04%
75,774
-1,694
-2% -$18.3K
NOTV
240
DELISTED
Inotiv
NOTV
$690K 0.04%
139,759
-11,041
-7% -$137K
CVX icon
241
Chevron
CVX
$382B
$671K 0.04%
3,737
-300
-7% -$52.4K
URGN icon
242
UroGen Pharma
URGN
$2.26B
$647K 0.04%
72,931
-1,500
-2% -$14.2K
ABT icon
243
Abbott
ABT
$188B
$591K 0.03%
5,386
-1,400
-21% -$145K
BRK.A icon
244
Berkshire Hathaway Class A
BRK.A
$1.14T
$469K 0.03%
1
– –
XOM icon
245
ExxonMobil
XOM
$662B
$464K 0.03%
4,203
-57
-1% -$6.11K
SYY icon
246
Sysco
SYY
$40.1B
$438K 0.03%
5,727
– –
HAS icon
247
Hasbro
HAS
$13.3B
$433K 0.02%
7,092
-553
-7% -$34.5K
J icon
248
Jacobs Solutions
J
$17.2B
$426K 0.02%
4,286
– –
YMAB
249
DELISTED
Y-mAbs Therapeutics
YMAB
$425K 0.02%
87,090
-3,575
-4% -$26K
MRK icon
250
Merck
MRK
$323B
$416K 0.02%
3,751
-1,457
-28% -$149K
8 9
10
11 12

Similar funds

RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
IL
Investure LLC Charlottesville, Virginia $2.04B AUM 15.91% 1-Year Est. Return
BC
BIT Capital Berlin, Germany $2.07B AUM 157.17% 1-Year Est. Return
SAM
Southeastern Asset Management Memphis, Tennessee $2.03B AUM 7.06% 1-Year Est. Return
AG
Avala Global New York $2.08B AUM 87.66% 1-Year Est. Return
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM

Rice Hall James & Associates's Q4 2022 Portfolio in Review

As of Q4 2022, Rice Hall James & Associates held 276 positions worth $1.74B, up 1.1% from $1.72B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Rice Hall James & Associates withdrew a net $61.5M in Q4 2022, closing 16 positions and reducing 193 holdings. Its most notable exit was Aerie Pharmaceuticals, an estimated $24.3M position sold in full.

By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Industrials.

Against the trend, Rice Hall James & Associates opened a new position in OmniAb worth $8.94M.

  • Rice Hall James & Associates's largest Q4 2022 buy was OmniAb: 2,483,766 shares worth $8.94M.
  • Rice Hall James & Associates added most to Doximity in Q4 2022, an estimated $10.2M increase.
  • Rice Hall James & Associates's biggest Q4 2022 reduction was Ligand Pharmaceuticals, cutting an estimated $12.3M.
  • Rice Hall James & Associates fully exited Aerie Pharmaceuticals in Q4 2022, selling an estimated $24.3M.
  • Rice Hall James & Associates's ten largest holdings make up 24% of its $1.74B portfolio in Q4 2022.
  • Rice Hall James & Associates opened 11 new positions and closed 16 in Q4 2022.
  • Rice Hall James & Associates's portfolio value rose 1.1% quarter-over-quarter to $1.74B.

Based on Rice Hall James & Associates's 13F filing for Q4 2022, filed 27 Jan 2023.